Gsa Capital Partners LLP Homology Medicines, Inc. Transaction History

Gsa Capital Partners LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$1.09 - $2.04 $45,883 - $85,873	-42,095 Reduced 39.37%	64,818 $82,000
Q3 2022 Nov 14, 2022	SELL	$1.55 - $3.01 $33,232 - $64,534	-21,440 Reduced 16.7%	106,913 $172,000
Q2 2022 Aug 09, 2022	SELL	$1.39 - $3.12 $139,016 - $312,037	-100,012 Reduced 43.79%	128,353 $253,000
Q1 2022 May 11, 2022	BUY	$2.6 - $4.17 $85,199 - $136,646	32,769 Added 16.75%	228,365 $694,000
Q4 2021 Feb 14, 2022	BUY	$3.64 - $7.78 $222,436 - $475,428	61,109 Added 45.44%	195,596 $712,000

Q3 2021 Nov 12, 2021	SELL	$6.01 - $8.71 $154,354 - $223,698	-25,683 Reduced 16.03%	134,487 $1.06 Million
Q2 2021 Aug 05, 2021	BUY	$6.02 - $9.64 $730,593 - $1.17 Million	121,361 Added 312.71%	160,170 $1.16 Million
Q1 2021 May 10, 2021	BUY	$9.17 - $14.8 $236,320 - $381,410	25,771 Added 197.66%	38,809 $365,000
Q4 2020 Feb 03, 2021	SELL	$8.92 - $13.29 $169,988 - $253,267	-19,057 Reduced 59.38%	13,038 $147,000
Q3 2020 Nov 06, 2020	BUY	$9.94 - $16.59 $319,024 - $532,456	32,095 New	32,095 $343,000

66.2K

Ticker FIXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,402,000
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.